id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-310597-zy6ckr53	Essa, Hani	Hypertension management in cardio-oncology	2020-08-03		.txt	text/plain	4756	261	35	The aetiology of hypertension in cardio-oncology is complex and multifactorial based on the type of chemotherapy, type of malignancy and intrinsic patient factors such as age and pre-existing comorbidities. In the absence of evidence demonstrating otherwise, hypertension in cardio-oncology should be managed utilising the same treatment guidelines for the general population. The increase in cancer survivors has been accompanied by increasing cardiovascular disease (CVD) morbidity and mortality due to downstream side effects of treatment and an increasing age of patients due to improved survival. Furthermore, the utilisation of antihypertensives to control high BP has no effect on treatment outcome, suggesting that there is no contraindication to managing hypertension properly in patients treated with angiogenesis inhibitors [53] . These patients should be monitored closely during their chemotherapy (especially if angiogenesis inhibitors are utilised) and post treatment for the development of hypertension. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway	./cache/cord-310597-zy6ckr53.txt	./txt/cord-310597-zy6ckr53.txt